Pharvaris N.V. (NASDAQ:PHVS – Get Free Report) CFO David Nassif sold 6,000 shares of the stock in a transaction dated Monday, September 21st. The shares were sold at an average price of $36.47, for a total value of $218,820.00. Following the completion of the sale, the chief financial officer directly owned 114,300 shares of the company’s stock, valued at approximately $4,168,521. The trade was a 4.99% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
Pharvaris Stock Down 4.1%
NASDAQ:PHVS traded down $1.43 during trading hours on Wednesday, reaching $33.77. The company had a trading volume of 148,429 shares, compared to its average volume of 411,839. The firm has a market cap of $2.21 billion, a price-to-earnings ratio of -11.06 and a beta of -2.33. The business’s 50-day simple moving average is $35.41 and its two-hundred day simple moving average is $31.88. Pharvaris N.V. has a twelve month low of $20.65 and a twelve month high of $43.25.
Pharvaris (NASDAQ:PHVS – Get Free Report) last posted its earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). As a group, equities analysts predict that Pharvaris N.V. will post -3.12 earnings per share for the current year.
Analysts Set New Price Targets
Get Our Latest Stock Report on Pharvaris
Hedge Funds Weigh In On Pharvaris
Several institutional investors have recently made changes to their positions in the business. Engineers Gate Manager LP purchased a new position in shares of Pharvaris during the 2nd quarter worth $1,143,000. Amundi raised its stake in Pharvaris by 61.4% during the 2nd quarter. Amundi now owns 49,944 shares of the company’s stock worth $1,727,000 after acquiring an additional 18,992 shares during the period. Moore Capital Management LP bought a new stake in Pharvaris during the 2nd quarter worth approximately $1,522,000. Alyeska Investment Group L.P. lifted its holdings in Pharvaris by 225.5% during the second quarter. Alyeska Investment Group L.P. now owns 406,829 shares of the company’s stock valued at $14,068,000 after purchasing an additional 281,829 shares in the last quarter. Finally, Wellington Management Group LLP lifted its holdings in Pharvaris by 12.9% during the second quarter. Wellington Management Group LLP now owns 2,392,934 shares of the company’s stock valued at $82,748,000 after purchasing an additional 274,034 shares in the last quarter.
About Pharvaris
Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.
Pharvaris’ lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.
Featured Articles
- Five stocks we like better than Pharvaris
- Sandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock?
- These 4 Companies Are Monetizing AI Today
- Quantum and Rare Earths? Implications of the Pasqal/USAR Partnership
- Lockheed’s Stock Hasn’t Priced In Its Own Backlog—Boeing’s Might Already Have
Receive News & Ratings for Pharvaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharvaris and related companies with MarketBeat.com's FREE daily email newsletter.
